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Vascular endothelial growth factor induces protein synthesis in
renal epithelial cells: A potential role in diabetic nephropathy.
Background. Vascular endothelial growth factor (VEGF) is
an important determinant of ocular complications of diabetes.
Its potential role in diabetic renal disease has not been exten-
sively studied.
Methods. We employed mice with streptozotocin-induced
type 1 diabetes and db/db mice with type 2 diabetes to study
the regulation of renal VEGF. Studies of VEGF regulation
of protein synthesis were performed using proximal tubular
epithelial (MCT) cells in culture.
Results. A nearly three-fold increase of VEGF165 expres-
sion in the renal cortex was seen, coinciding with renal hyper-
trophy in mice with either type 1 or type 2 diabetes. VEGF
increased de novo protein synthesis and induced significant
hypertrophy in MCT cells. VEGF stimulation of protein syn-
thesis was dependent on tyrosine phosphorylation of the type 2
VEGF receptor and phosphatidylinositol 3-kinase (PI 3-kinase)
activity. Activity of Akt was increased two- to three-fold by
VEGF. Expression of dominant-negative Akt showed that Akt
activation was also needed for VEGF-induced protein synthe-
sis and cell hypertrophy. As PI 3-kinase-Akt axis regulates
initial events in protein translation, these events were examined
in the context of VEGF regulation of protein synthesis. VEGF
stimulated eukaryotic initiation factor 4E-binding protein (4E-
BP1) phosphorylation, which was dependent on activation of
PI 3-kinase and Akt. Stable transfection with 4E-BP1 Thr37,46-
Ala37,46 mutant abolished the VEGF-induced de novo protein
synthesis and cell hypertrophy.
Conclusion. VEGF augments protein synthesis and induces
hypertrophy in MCT cells in a PI 3-kinase– and Akt-dependent
manner. Phosphorylation of Thr37,46 in 4E-BP1 is required for
VEGF-induced protein synthesis and hypertrophy in MCT
cells. These data suggest a role for VEGF in the pathogenesis
of diabetic renal disease.
Signaling events play a central role in regulation of
synthesis of proteins and extracellular matrix compo-
1 See Editorial by Ziyadeh and Wolf, p. 758.
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nents. Recently, we reported activation of phosphatidyl-
inositol 3-kinase (PI 3-kinase) and Erk kinase pathways
in the renal cortex of mice with type 2 diabetes that
coincide with the onset of hypertrophy and matrix accu-
mulation [1]. We could attribute only a part of the activa-
tion of these pathways in the kidney in type 2 diabetes
to insulin receptor activation, suggesting involvement of
other growth factors [1]. Among the putative growth
factors, we considered activation of vascular endothelial
growth factor (VEGF) in the diabetic kidney. There is
good evidence that VEGFs are intimately involved in
ocular complications of diabetes. VEGF concentrations
are increased in vitreous and aqueous humors in retinop-
athy caused by diabetes [2]. Neutralization of VEGF
expression with soluble VEGF receptors [3, 4], antibod-
ies [5], or antisense oligonucleotides [6] results in amelio-
ration of neovascularization in the diabetic retina.
However, the role of VEGF in diabetic renal disease
is not as well studied. Increases in expression of both
VEGF and its receptor have been reported in the kidney
in rodents with type 1 or type 2 diabetes [7, 8]. Being a
vascular permeability factor, VEGF may be involved
in proteinuria, as suggested by reduction in proteinuria
following administration of antibody against VEGF [9].
However, VEGF may be involved in cellular events be-
yond the capillary in the diabetic kidney. As we found
an increase in renal cortical VEGF expression in both
type 1 and type 2 diabetes coinciding with renal hypertro-
phy, it is conceivable that VEGF affects cellular pro-
cesses involved in renal growth (i.e., protein synthesis).
Although VEGF regulation of capillary formation and
function of endothelial cells has been extensively studied,
there is insufficient understanding of its nonangiogenic
properties (e.g., protein synthesis) particularly in cells of
nonendothelial lineage. In this study, we studied VEGF
regulation of protein synthesis in proximal tubular epi-
thelial (MCT) cells, which form the bulk of cells in the
renal cortex and account for much of the renal hypertro-
phy in conditions such as diabetes and compensatory
renal growth.
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METHODS
Animal models of diabetes
Mice with type 1 or type 2 diabetes were studied. To
induce type 1 diabetes, C57 BLK mice received three to
four daily intraperitoneal injection of streptozotocin 0.5
g/g in citrate buffer (pH 4.5) [10]. Littermate control
mice were injected with the vehicle only. To study type
2 diabetes, db/db mice with type 2 diabetes were em-
ployed. These mice spontaneously develop diabetes at
about 6 weeks of age. Lean littermate db/m mice were
employed as control. On day 3 of hyperglycemia, mice
with type 1 diabetes and their respective controls were
anesthetized and the kidneys were harvested. Due to
variability of onset of diabetes in individual mice, db/db
mice with type 2 diabetes were sacrificed on approxi-
mately day 14 of diabetes. Kidney weight and plasma
glucose were measured in control and diabetic mice.
Cell culture
SV40-transformed murine proximal tubular epithelial
(MCT) cells (kindly provided by Eric Neilson, Vander-
bilt University, Nashville, TN, USA) were grown in Dul-
becco’s modified Eagle’s medium (DMEM) containing
7% fetal bovine serum (FBS), 5 mmol/L glucose, and
no insulin [11, 12]. These cells express in vivo properties
of MCT cells [13]. Nearly confluent monolayers of cells
were serum-deprived for 18 hours before experiments.
Detection of VEGF
Equal amounts (200g) of renal cortical homogenates
from control and type 1 diabetic mice were immunopre-
cipitated with 1:2000 dilution of anti-VEGF165 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
immune complexes were separated on a 15% sodium
dodecyl sulfate-polyacrylamide electrophoresis (SDS-
PAGE) gel. VEGF165 is the isoform most commonly
expressed in the kidney. Following transfer overnight to
a nitrocellulose membrane, the membrane was blocked
in non-fat dry milk as previously described [12]. Immu-
noblotting was performed with 1:2000 dilution of the
same anti-VEGF antibody, and reactive bands detected
by chemiluminescence with an enhanced chemilumines-
cence (ECL) kit. An aliquot of renal cortical homogenate
was run on a 15% SDS-PAGE gel and immunoblotted
with an antibody against actin to confirm that an equal
amount of protein was employed for immunoprecipita-
tion. In mice with type 2 diabetes, immunoblotting with
anti-VEGF165 antibody was sufficient for detection of
VEGF. The membrane was stripped and immunoblotted
for actin to assess loading.
Protein synthesis measurement
The protocol has been described in detail [12]. Serum-
starved cells were incubated with 10, 20, and 50 ng/mL
of VEGF165 in the presence of 10Ci/mL of [35S]-methio-
nine for 2 hours. Cells were then washed in phosphate-
buffered saline (PBS) and lysed in radioimmunoprecipi-
tation assay (RIPA) buffer. Protein (20g/g) was spotted
onto 3 mm paper (Whatman International, Maidstone,
UK). The filters were then washed by boiling them for
1 minute in 10% trichloroacetic acid containing 0.1 g/L
methionine. This was repeated three times. The filters
were then dried and immersed in scintillation medium
before determining radioactivity.
PI 3-kinase assay
Control and VEGF-treated cells were homogenized in
the RIPA buffer [11, 12]. Equal amounts of homogenates
(300 g) were immunoprecipitated using antiphospho-
tyrosine antibody (Upstate Biotechnology, Lake Placid,
NY, USA) in the presence of immunoglobulin G (IgG)-
Sepharose beads. Immunobeads were incubated with
10 g phosphatidylinositol for 10 minutes at 25C, fol-
lowed by the addition of 20 mmol magnesium chloride,
5 Ci of [-32P] adenosine triphosphate (ATP) for 10
minutes at 25C. The reaction was stopped by the addi-
tion of a mixture of chloroform-methanol and 11.6 N
HCl at a ratio of 50:100:1. The reactants were extracted
with 100 L of chloroform and the organic layer was
washed with methanol and 1 N HCl in a 1:1 ratio. Reac-
tion products were dried, resuspended in chloroform,
separated by thin layer chromatography, and the spots
were visualized by autoradiography.
Akt/PKB kinase assay
Equal amounts (300 g) of MCT cell lysates from
control and treated cells were immunoprecipitated with
an anti-Akt/PKB antibody (Upstate Biotechnology)
[12]. Protein G Sepharose beads were added and incu-
bated at 4C for 1 hour. The beads were washed and
Akt assay was performed in the presence of 50 mol of
ATP, 1 Ci of [ -32P] ATP, and 5 g of myelin basic
protein (MBP) at 30C for 30 minutes. The reaction was
stopped by the addition of an equal volume of 2 sample
buffer. Phosphorylated bands were detected by SDS-
PAGE, followed by autoradiography. Western blotting
with an anti-Akt/PKB antibody (Upstate Biotechnology)
was performed on an aliquot of the assay lysates to assess
the loading. Additionally, equal amounts of cell lysates
were immunoblotted with a phospho-specific antibody
that recognizes Akt phosphorylated on the Ser473 (Cell
Signaling Technology, Beverly, MA, USA).
Analysis of 4E-BP1 phosphorylation
Immunoblotting with anti-4E-BP1 antibody (Santa
Cruz Biotechnology) or anti-phospho-4E-BP1 antibody
(Cell Signaling Technology) was performed as previously
described [11, 12].
The phospho-specific antibody detects 4E-BP1 that is
phosphorylated on the Thr70 residue.
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Adenovirus infection
Replication-defective adenovirus vector–carrying
mouse Akt mutated at its phosphorylation sites (T308A,
S473A) [14] was employed in investigation of the role
of Akt in VEGF regulation of protein synthesis. The
dominant-negative (DN) Akt carries a hemagglutinin
(HA) tag. Cells were quiesced in serum-free medium for
24 hours and infected with 70 MOI of HA-tagged Ad-
DN-Akt, at room temperature for 1 hour, as previously
described [15]. Control cells were infected adenovirus-
carrying green fluorescent protein (Ad-GFP). Following
incubation for 24 hours in serum-free medium, cells were
treated with VEGF for 2 hours and protein synthesis
measured as described above.
Transfection studies
In order to evaluate the role of 4E-BP1 in VEGF
regulation of protein synthesis, we employed stable
transfection with plasmids carrying 4E-BP1 mutant
(pACTAG-BP1 Thr37,46→Ala37,46). The mutant 4E-BP1
does not undergo phosphorylation of Thr37,46 and remains
bound to eIF4E. For control, we employed a plasmid
vector that does not contain a 4E-BP1 insert. Plasmids
(up to 5 g) were mixed with 250 L of Optimem me-
dium and 25 L lipofectamine, and incubated for 15
minutes at room temperature, followed by addition of
750 L of Optimem medium. Cell layers grown in 10 cm
dishes were washed in serum-free medium, and the DNA
lipofectamine mixture was added. After 6 hours at 37C,
serum-supplemented medium containing neomycin was
added. Cells resistant to neomycin were cloned and prop-
agated. As the mutant protein is tagged with HA, effi-
ciency of transfection was monitored by immunoblotting
with a monoclonal anti-HA antibody (Covarice, Princeton,
NJ, USA). The effectiveness of the plasmids has been
recently demonstrated [16].
Statistics
Data from a minimum of three experiments were ex-
pressed as mean  SEM, and analyzed by analysis of
variance (ANOVA) for comparison between multiple
groups; P values of  0.05 were considered significant.
RESULTS
VEGF expression is increased in renal cortex in early
stage of type 1 or type 2 diabetes
Compared to control mice (N 7), on day 3 of disease,
mice with streptozotocin-induced type 1 diabetes (N 
9) had higher plasma glucose concentrations (17.97 
2.5 mmol/L vs. 7.48 0.82 mmol/L, P 0.0001) and higher
kidney weight (26%, P  0.0001) (Fig. 1). Due to vari-
ability in onset of diabetes in individual mice, a 14-day
period after the onset of diabetes in the first mouse was
chosen as the early phase in db/db mice with type 2
diabetes. At this time, db/db mice with type 2 diabetes
(N  5) relative to db/m control (N  5) had higher
concentrations of plasma glucose (14.1  1.5 mmol/L vs.
7.8  0.3 mmol/L, P  0.005), and higher kidney weight
(32%, P 0.005) (Fig. 1). These data are consistent with
hypertrophy of the kidney in both types of diabetes. We
evaluated whether VEGF expression was regulated at
the time renal hypertrophy was evident. Immunoblotting
with antibody against VEGF165, the main isoform of
VEGF expressed in the kidney, detected VEGF as a
protein of 46 kD. Net VEGF expression was increased
nearly 3.2-fold and 2.9-fold relative to control in renal
cortex of mice with type 1 or type 2 diabetes, respectively,
following correction for loading (Fig. 1).
VEGF stimulates protein synthesis MCT cells
Augmented VEGF expression coinciding with renal
hypertrophy in diabetic mice suggests that VEGF may
promote protein synthesis and induce hypertrophy in
renal cells. We examined VEGF regulation of protein
metabolism in MCT cells, which form the bulk of renal
cortex. Serum-starved MCT cells were incubated with
VEGF (10 to 50 ng/mL) in the presence of [35S]-methio-
nine for 2 hours. As shown in Figure 2A, VEGF in-
creased de novo protein synthesis with peak effect at 20
ng/mL (30.5%, P  0.0006). The main VEGF receptors
that mediate actions of VEGF are receptor tyrosine ki-
nases [17]. We sought to identify the receptors involved
in VEGF-regulation of protein synthesis. Immunoblot-
ting revealed expression of the type 2 VEGF receptor
KDR/Flk-1 (Fig. 2B); we could not detect the presence
of type 1 receptor in preliminary experiments. VEGF
robustly induced tyrosine phosphorylation of the type 2
receptor within 15 minutes; preincubation with SU1498,
an agent that selectively inhibits actions of the type 2
VEGF receptor, prevented increase in tyrosine phos-
phorylation in VEGF-treated cells (Fig. 2C). Potential
involvement of the type 2 VEGF receptor in protein
synthesis was evaluated with the inhibitor. SU1498 com-
pletely inhibited de novo protein synthesis induced by
VEGF (Fig. 2D), confirming recruitment of type 2 VEGF
receptor in VEGF regulation of protein synthesis. These
data show that VEGF promotes protein synthesis that
would be consistent with a putative role in inducing renal
hypertrophy in diabetes. Signaling pathways involved in
VEGF regulation of protein synthesis downstream from
type 2 VEGF receptors were therefore investigated.
VEGF stimulates PI 3-kinase activity
PI 3-kinase activation is important for stimulation of
protein synthesis by growth factors, such as insulin, that
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Fig. 1. Renal hypertrophy in diabetic mice. (A and C ) To induce type
1 diabetes, C57BLK mice (N 7) received three to four daily intraperi-
toneal injections of streptozotocin 0.5 g/g body weight, whereas the
control mice (N  9) received vehicle only. Data were collected on day
3 after onset of hyperglycemia. Mice with type 2 diabetes (db/db) (N
 5) and their nondiabetic lean littermate control (N  5) were studied
in the first two weeks of disease. Data on kidney weight are shown as
histograms. The mean kidney weight was increased in mice with type
1 (*P  0.0001) or type 2 diabetes (*P  0.005). (B and D ) Vascular
endothelial growth factor (VEGF) expression is increased in renal cor-
tex coinciding with hypertrophy of the kidney in type 1 or type 2
diabetes. Type 1 diabetes: Equal amounts of renal cortical homogenates
from control and diabetic mice were immunoprecipitated with an anti-
body against VEGF165. Immune complexes were fractionated on a
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel and immunoblotted with the same antibody. Type 2 dia-
activate receptor tyrosine kinases [18]. As VEGF recep-
tors are also tyrosine kinases, we examined whether PI 3-
kinase was activated following VEGF stimulation. Se-
rum-starved MCT cells were stimulated with VEGF (20
ng/mL) for 0 to 30 minutes. Equal amounts of proteins
were immunoprecipitated with either antiphosphotyro-
sine antibody or p85 subunit of PI 3-kinase antibody,
and kinase activity in immune complexes was measured
using phosphatidylinositol as a substrate. Incubation
with VEGF resulted in a robust increase in PI 3-kinase
activity within 2 minutes that peaked at 15 minutes and
began to wane by 30 minutes (Fig. 3 A, B). The increment
in VEGF-stimulated PI 3-kinase activity was completely
inhibited by preincubation with 25 mol LY294002, an
inhibitor of PI 3-kinase (Fig. 3C). At this concentration,
LY294002 was able to completely abolish VEGF-induced
de novo protein synthesis (Fig. 3D).
Akt activation is needed for VEGF stimulation of
protein synthesis
In many growth factor–driven signaling pathways, Akt
(PKB) is an immediate downstream target for PI 3-kinase,
although PI 3-kinase–independent pathways of Akt acti-
vation have also been described recently [19]. We next
investigated whether VEGF activated Akt/PKB, and if
this was PI 3-kinase–dependent. Serum-starved MCT
cells were stimulated with VEGF for 15 minutes. VEGF
increased Akt/PKB activity by nearly 3-fold, as shown
by immunoblotting with an antibody specific for Akt
phosphorylated on Ser473 (Fig. 4A). These observations
were confirmed by a direct immunokinase assay, em-
ploying Akt immunoprecipitates and myelin basic pro-
tein (MBP) as a substrate (Fig. 4B). Preincubation with
25 mol/L LY294002 for 30 minutes abolished VEGF-
induced Akt activity (Fig. 4 A, B), suggesting that it was
dependent on stimulation of PI 3-kinase.
Having demonstrated Akt activation by VEGF, we
evaluated its requirement for stimulation of de novo
protein synthesis by the growth factor by employing a
dominant-negative construct. Infection of MCT cells
with HA-tagged Ad-DN-Akt was maximal at 24 hours,
as shown by immunoblotting with antibody against HA
(Fig. 4C). Ad-GFP–infected control cells and cells car-
rying Ad-DN-Akt were incubated with or without
VEGF, and regulation of protein synthesis was studied.
As shown in Figure 4D, VEGF-stimulated protein syn-
betes: Equal amounts of renal cortical homogenates were separated on
a 15% SDS-PAGE gel and immunoblotted with anti-VEGF antibody.
Each lane represents data from an individual animal. Note the almost
3-fold increase in VEGF protein expression in renal cortex of mice
with either type 1 or type 2 diabetes in relation to their respective
controls. Immunoblotting for actin was employed to assess loading, as
shown in lower panels.
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Fig. 2. Vascular endothelial growth factor (VEGF) stimulates protein
synthesis in proximal tubular cell (MCT) cells. (A ) Serum-starved cells
were stimulated with different concentrations of VEGF, and cells were
labeled with [35S]-methionine for 2 hours. Incorporation of the label
into trichloroacetic acid (TCA)-precipitable protein was measured, and
expressed as percentage of control (N 12, mean SE, from 3 individ-
ual experiments, *P 0.0006) compared with control. (B ) Cell homoge-
nates were fractionated on a 7.5% gel by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Following transfer to a
nitrocellulose membrane, immunoblotting was performed using 1:1000
dilution of an antibody that specifically detects the type 2 VEGF recep-
tor. Data are shown in triplicate. (C ) MCT cells were incubated with
or without VEGF 20 ng/mL for 15 minutes with or without preincuba-
tion with 2 mol/L SU1498, a VEGFR2-selective inhibitor, for 30 min-
utes. Equal amounts of cell homogenates were immunoprecipitated
with antibody against type 2 VEGF receptor. Immune complexes were
separated on 7.5% SDS PAGE gel, and immunoblotted with anti-
phosphotyrosine antibody. Representative data from two experiments
are shown. The membrane was stripped and blotted with antibody
against type 2 VEGF receptor to assess loading. (D ) Serum-starved
cells were preincubated with or without 2 mol/L SU1498 followed
thesis was significantly inhibited in cells infected with
Ad-DN-Akt, but not in control cells carrying AdGFP.
Next, we aimed to identify steps in the protein synthe-
sis pathway that were regulated by PI 3-kinase and Akt.
Because these kinases control initiation events in protein
translation [12, 20], we extended our studies to regulation
of phosphorylation of 4E-BP1, a repressor of the initia-
tion phase of protein translation.
VEGF stimulates phosphorylation of 4E-BP1, which is
PI 3-kinase- and Akt-dependent
The initiation phase of protein translation is rate lim-
iting in regulation of protein synthesis [21]. The initiation
phase is under the control of eukaryotic initiation factor
4E (eIF4E), an mRNA cap binding protein. In the resting
state eIF4E is held in an inactive heterodimeric complex
by its binding protein, 4E-BP1. Phosphorylation of 4E-
BP1 results in dissolution of the heterodimeric complex,
freeing the eIF4E to bind to mRNA cap and promote
initiation of peptide chain formation [20]. PI 3-kinase
and Akt regulate phosphorylation of 4E-BP1 and disso-
ciation of eIF4E-4E-BP1 complex in cells treated with
agents that stimulate protein synthesis (e.g., insulin, an-
giotensin II) [11, 12].
We examined whether increase in protein synthesis by
VEGF involved regulation of 4E-BP1 phosphorylation.
Serum-starved MCT cells were incubated with VEGF,
and lysates were immunoblotted with anti-phospho-4E-
BP1 antibodies. This antibody detects only the phopho-
rylated isoforms of 4E-BP1. The upper band ( band)
is more phosphorylated than the lower band ( band)
and migrates more slowly. Increase in the intensity of
the upper  band reflects a greater increase in 4E-BP1
phosphorylation. Stimulation of 4E-BP1 phosphoryla-
tion by VEGF was maximal at 15 minutes, as indicated by
the increased intensity of the  band (Fig. 5A). Western
blotting with an antibody against 4E-BP1 reveals three
bands—in addition to the aforementioned phosphory-
lated  and  bands, the unphosphorylated 	 band is
detected as the fastest migrating isoform. Immunoblot-
ting with anti-4E-BP1 showed VEGF increased the in-
tensity of  band, confirming the observations made with
phospho-specific antibody (Fig. 5A). The effect of VEGF
on phosphorylation of 4E-BP1 was concentration-depen-
dent, with a maximal effect observed at 20 ng/mL, which
was also the concentration that stimulated maximal pro-
tein synthesis (data not shown). We next examined sig-
naling events involved in VEGF regulation of 4E-BP1
by treatment with or without VEGF 20 ng/mL, in the presence of
[35S]-methionine at 10 Ci/mL for 2 hours. Incorporation of the label
into TCA-precipitable protein was expressed as percentage of control
(N  12, mean  SE). *P  0.0001 VEGF compared to control; **P 
0.0001 VEGF 
 SU1498 compared to VEGF.
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Fig. 3. Vascular endothelial growth factor (VEGF)-stimulated phosphatidylinositol (PI) 3-kinase activity is required for VEGF-induced protein
synthesis. (A and B ) Equal amounts of lysates from serum-starved proximal tubular cell (MCT) cells with or without incubation with VEGF (20
ng/mL) for indicated times were immunoprecipitated with an antiphosphotyrosine antibody (A) or an antibody against p85 subunit of PI 3-kinase
(B). Kinase activity in immune complexes was measured using phosphatidylinositol as a substrate. Phospholipids were separated by thin-layer
chromatography and visualized by autoradiography. A representative blot from two individual experiments is shown. PIP refers to phosphatidylinosi-
tol 3 phosphate, the end product of PI 3-kinase activity. (C ) MCT cells were incubated with or without VEGF for 15 minutes, with or without
preincubation with 25 mol/L LY294002 for 30 minutes. PI 3-kinase activity in the anti-p85 immune complexes was determined as described in
(B). A representative blot from two individual experiments is shown. (D ) MCT cells were incubated with or without VEGF for 15 minutes, with
or without preincubation with 25mol LY294002 for 30 minutes. Incorporation of [35S]-methionine into de novo synthesized proteins was determined
as described in Figure 2. Composite data from three individual experiments are shown (N  12 at each point). *P  0.001 VEGF compared to
control; ** P  0.001 VEGF compared to VEGF 
 LY294002.
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Fig. 4. Vascular endothelial growth factor (VEGF)-stimulated Akt activity is phosphatidylinositol (PI) 3-kinase-dependent and is needed for
VEGF-induced protein synthesis. (A and B ) Proximal tubular cell (MCT) cells were incubated with or without VEGF for 15 minutes, with or
without 30 minutes preincubation with LY294002. Akt kinase activity was determined by immunoblotting with a phospho-specific antibody that
specifically binds to Akt phosphorylated on Ser473 (A). Akt activity was also measured by an in vitro kinase assay using myelin basic protein (MBP)
as a substrate (B). Immunoblotting with Akt antibody was done to assess loading. A representative blot from three individual experiments is
shown. (C ) Serum-starved cells were infected with 70 MOI of hemagglutinin (HA)-tagged Ad-DN-Akt dominant-negative construct (DN-Akt)
for different durations of incubation. Equal amounts of cell homogenates were separated on 15% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel and immunoblotted with an HA antibody. Maximal expression was seen at 24 hours. Loading was assessed by
immunoblotting with anti-actin antibody (lower panel). (D ) Following infection with the Ad-DN-Akt dominant negative vector or Ad-GFP control
vector in serum-free medium for 24 hours, cells were processed for VEGF regulation of protein synthesis as described in Figure 2. Composite
data from three experiments are expressed as percentage of control. (N  7, 3 experiments, mean  SE, *P  0.0001 VEGF compared to control;
**P  0.0001 VEGF compared to VEGF 
 Ad-DN-Akt). The upper panel shows detection of HA by immunoblot only in the Ad-DN-Akt
infected cells.
phosphorylation. Serum-starved MCT cells were stimu-
lated with VEGF with or without preincubation with
LY294002. As shown in the Figure 5B, LY294002 com-
pletely abrogated VEGF-induced 4E-BP1 phosphoryla-
tion, as shown by disappearance of the highly phosphory-
lated  band and increase in the intensity of the less
phosphorylated  band in a immunoblot employing
phospho-specific antibody; these observations were con-
firmed by Western blotting with anti-4E-BP1 antibody (Fig.
5B). These data suggest a requirement for PI 3-kinase
activation in VEGF induction of 4E-BP1 phosphorylation.
As described above, Akt activation is downstream from
PI 3-kinase in VEGF-treated MCT cells. Akt activation
is required for 4E-BP1 phosphorylation in insulin-treated
cells [16]. We investigated whether Akt activation was
required for VEGF-activation of 4E-BP1. Serum-starved
Ad-GFP (control) and Ad-DN-Akt–infected cells were
incubated with or without VEGF, and 4E-BP1 phosphory-
lation was assessed by Western blotting with the phos-
pho-4E-BP1 specific antibody. VEGF augmented 4E-BP1
phosphorylation in cells infected with Ad-GFP, as indi-
cated by greater intensity of the  band. However, VEGF
failed to increase 4E-BP1 phosphorylation in cells in-
fected with Ad-DN-Akt (Fig. 5C), as suggested by the
lack of increase in  band phosphorylation and dispro-
portionate increase in intensity of the less phosphory-
lated band. These data demonstrate that Akt activation
is needed for VEGF induction of 4E-BP1 phosphoryla-
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Fig. 5. Vascular endothelial growth factor (VEGF) stimulates 4E-BP1
phosphorylation that is phosphatidylinositol (PI) 3-kinase- and Akt-
dependent. (A ) Serum-starved proximal tubular cell (MCT) cells were
incubated with 20 ng/mL VEGF for different durations and equal
amounts of the homogenates were separated on a 15% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Following
transfer to a nitrocellulose membrane, immunoblotting was performed
with anti-phospho-4E-BP1 antibody, which detects 4E-BP1 phosphory-
lated on Thr70. A representative blot from three experiments is shown.
The lower panel shows an immunoblot with anti-unphosphorylated 4E-
BP1 antibody. (B ) Serum-starved MCT cells were incubated with or
without VEGF 20 ng/mL for 15 minutes with or without preincubation
with 25 mol LY294002. Immunoblotting with anti-phospho 4E-BP1
antibody was performed as described in (A). A representative blot from
four experiments is shown. The lower panel shows an immunoblot using
anti-unphosphorylated 4E-BP1 antibody. (C ) Following infection with
the Ad-DN-Akt or Ad-GFP control vector in serum-free medium for
1 hour, MCT cells were incubated with or without VEGF 20 ng/mL
for 15 minutes. Immunoblotting with anti-phospho 4E-BP1 antibody
was performed as described in (A). A representative blot from two
experiments is shown. The middle panel shows detection of hemaggluti-
nin (HA) by immunoblot only in the Ad-Akt infected cells. The lower
panel shows an immunoblot employing anti-unphosphorylated 4E-BP1
antibody.
tion. Successful infection of the virus was monitored by
immunoblotting for HA tag (Fig. 5C). Western blotting
with anti-native 4E-BP1 antibody confirmed data ob-
tained with phospho-specific 4E-BP1 antibody (Fig. 5C).
4E-BP1 phosphorylation is required for
VEGF-induced protein synthesis in MCT cells
Next, we examined the role of 4E-BP1 phosphoryla-
tion in VEGF-induced protein synthesis employing cells
stably transfected with the HA-tagged 4E-BP1 Thr37,46→
Ala37,46 mutant. Successful transfection was demonstrated
by detection of HA by immunoblotting. Cells transfected
with control vector and mutant 4E-BP1 plasmid were
stimulated with VEGF in the presence of [35S]-methio-
nine for 2 hours. Incorporation of the label into trichloro-
acetic acid (TCA)-precipitable protein was measured.
Representative data from 2 experiments (N  12) are
shown in Figure 6A. VEGF significantly increased the
incorporation of the label into protein in cells transfected
with control plasmid vector (P  0.0001). Transfection
with a plasmid carrying mutant 4E-BP1 completely in-
hibited VEGF-induced protein synthesis (P  0.0001),
compared to control vector–transfected cells treated with
VEGF (Fig. 6A). These observations suggest that phos-
phorylation of Thr37,46 residues on 4E-BP1 is required
for VEGF stimulation of protein synthesis in MCT cells.
VEGF induces cell hypertrophy that is dependent on
Akt and 4E-BP1
VEGF expression was increased in the renal cortex
at the time renal hypertrophy was evident, suggesting
VEGF may have a pathogenic role in the process. Having
demonstrated VEGF stimulation of protein synthesis,
we examined whether VEGF induces renal hypertrophy
in MCT cells in vitro. Following 24 hours of incubation,
VEGF (20 ng/mL) increased the amount of protein (g)
per 105 cells by 30% (control, 48.9  3.45 vs VEGF,
63.5  1.32, N  12 from 2 experiments, P  0.0076).
Under the same conditions, however, VEGF did not
increase DNA synthesis as evaluated by 3H-thymidine
incorporation in MCT cells (data not shown). We exam-
ined the role of Akt and 4E-BP1 in VEGF-induced hy-
pertrophy, employing the respective dominant-negative
constructs. VEGF was unable to induce hypertrophy in
cells infected with Ad-DN-Akt, unlike in control cells
infected with Ad-GFP (Fig. 6B). Transfection with 4E-
BP1 mutant also abolished VEGF-induced cell hypertro-
phy (Fig. 6C). These data demonstrate that activation
of Akt and phosphorylation of 4E-BP1 on Thr37,46 resi-
dues are required for VEGF induction of hypertrophy
in MCT cells.
DISCUSSION
Our data demonstrate that renal cortical VEGF ex-
pression is increased in the early stages of type 1 and
type 2 diabetes, coinciding with renal hypertrophy, sug-
gesting that VEGF may be involved in stimulating pro-
tein synthesis. Renal hypertrophy mainly involves cells
of the cortex, particularly MCT cells. In agreement with
in vivo observations, MCT cells in vitro demonstrated
augmented de novo protein synthesis and hypertrophy
in response to VEGF. Analysis of the signaling pathways
showed that activation of the PI 3-kinase-Akt axis is
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Fig. 6. 4E-BP1 phosphorylation is required for vascular endothelial
growth factor (VEGF)-induced protein synthesis. (A ) Proximal tubular
cell (MCT) cells were stably transfected with a plasmid carrying the
Thr37,46→Ala37,46 mutant employing lipofectamine, as described in Meth-
ods. Successful transfection was indicated by the detection of hemagglu-
tinin (HA) antigen by immunoblotting (upper panel). Control cells
were transfected with plasmid vector alone. Serum-starved vector- and
mutant 4E-BP1–transfected cells were incubated with 20 ng/mL VEGF
required for VEGF induction of protein synthesis and
hypertrophy. Furthermore, VEGF stimulation of protein
synthesis and hypertrophy is dependent on phosphoryla-
tion of distinct threonine residues on 4E-BP1, a major
regulator of the initiation phase of protein translation.
We have also shown that VEGF-induced phosphoryla-
tion of 4E-BP1 is dependent on activation of PI 3-kinase
and Akt.
Our observations implicate VEGF in renal growth that
characteristically occurs in the early phase of type 1 or
type 2 diabetes. Cells that secrete VEGF in the diabetic
kidney are yet to be fully identified. In the normal kidney,
the dominant form of VEGF-A (165 kD) [22] is derived
from podocytes [23]. In addition, MCT cells [24] may
also synthesize VEGF, particularly under stress (e.g.,
hypoxia) [25, 26]. As augmented VEGF expression was
seen in the renal cortex of mice with type 1 or type 2
diabetes, a common factor, such as hyperglycemia, could
be responsible [27]. However, agents of pathogenic im-
portance in diabetic renal disease, angiotensin II [28]
and transforming growth factor  (TGF-) [29] have
also been shown to promote VEGF expression.
In addition to synthesizing VEGF, renal cells also ex-
press VEGF receptors, suggesting that VEGF may regu-
late renal function. VEGF is known to signal through
three receptors that have intrinsic tyrosine kinase activ-
ity: Flt-1, or type 1, VEGF receptor; KDR/Flk-1, or type 2,
VEGF receptor, and Flk-4, or type 3, VEGF receptor
[30]. The type 3 VEGF receptor is commonly expressed
by lymphatic endothelium. Both type 1 and type 2 VEGF
receptors have been reported to be present in the kidney,
particularly on the glomerular endothelial cells [31].
Studies with labeled VEGF binding revealed intense
in the presence of [35S]-methionine at 10 Ci/mL for 2 hours. Incorpora-
tion of the label into trichloroacetic acid (TCA)-precipitable protein
was estimated and expressed as percentage of control (N  12, 2
experiments, data are expressed as mean  SE). *P  0.0001 VEGF
compared to control; **P  0.0001 VEGF compared to VEGF 
 4E-
BP1 mutant. (B ) MCT cells infected with either Ad-GFP or hemaggluti-
nin (HA)-tagged Ad-DN-Akt, as described in Figure 4 were incubated
with or without VEGF (20 ng/mL) for 24 hours. Protein contents of
cell layers were estimated and expressed per 105 cells. Note that VEGF
induced hypertrophy in Ad-GFP control cells but not in the Ad-DN-
Akt cells. (N  6, 2 experiments, data are expressed as mean  SE).
*P  0.0035 VEGF compared to control; **P  0.005 VEGF in control
cells compared to VEGF in Ad-DN-Akt cells. The lower panel shows
presence of HA tag only in Ad-DN-Akt infected cells. (C ) MCT cells
stably transfected with either a plasmid carrying Thr37,46→Ala37,46 mutant
of 4E-BP1 or an empty plasmid vector alone, as described in (A), were
incubated with or without VEGF (20 ng/mL) for 24 hours. Protein
content of cell layer was estimated and expressed per 105 cells. Successful
transfection was indicated by detection of HA antigen by immunoblot-
ting (upper panel). Note that VEGF induced hypertrophy in empty
vector transfected control cells but not in the 4E-BP1 mutant cells.
(N 12 to 18, 3 experiments, meanSE). *P 0.0001 VEGF compared
to control in control cells; **P 0.0001 VEGF in control cells compared
to VEGF in 4E-BP1 mutant cells.
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binding in the renal cortex [7], suggesting that other renal
cortical cells, including proximal tubular epithelial cells,
may also express VEGF receptors. We could easily de-
tect the type 2 VEGF receptor on MCT cells by immu-
noblotting, although expression of the type 1 receptor
was not readily evident. Inhibition of VEGF-stimulated
protein synthesis by SU1498 suggested involvement of
the type 2 receptor in regulation of protein metabolism
by VEGF. The type 2 VEGF receptor is also involved
in other crucial cellular responses to VEGF, such as
activation of nitric oxide synthase, proliferation, and mi-
gration [32].
We explored the signaling pathways recruited by type 2
VEGF receptors in regulation of protein synthesis. Re-
ceptor tyrosine kinases, such as the insulin receptor, com-
monly recruit docking proteins [e.g., insulin receptor sub-
strate-1 (IRS-1)] in their signaling pathways [33]. It is not
known whether signaling pathways of VEGF receptors
involve association of a docking protein. In a separate
study, we have found that within minutes of addition of
VEGF to MCT cells, the type 2 VEGF receptor binds
to IRS-1. Investigation with antisense IRS-1 oligos sug-
gested that this association is required for at least a part
of PI 3-kinase activation by VEGF [34]. Stimulation of
protein synthesis by ligands for receptor tyrosine kinases
such as insulin or insulin growth factor-1 (IGF-1) re-
quires the activation of PI 3-kinase [35]. We examined
whether VEGF regulated PI 3-kinase activity and if this
was needed for promoting protein synthesis. VEGF
promptly stimulated PI 3-kinase activity, and inhibition
of PI 3-kinase with LY294002 neutralized VEGF stimu-
lation of protein synthesis. Because PI 3-kinase activa-
tion is a relatively proximal event in VEGF receptor–
signaling, we examined the role of Akt, a downstream
target of PI 3-kinase, in VEGF-stimulated protein syn-
thesis. VEGF robustly activated Akt, which was predi-
cated upon activation of PI 3-kinase. Investigation with
Ad-DN-Akt demonstrated the requirement for Akt acti-
vation in VEGF-induced protein synthesis and cell hy-
pertrophy. As discussed below, Akt regulates crucial
early steps in the initiation phase of protein translation
(e.g., phosphorylation of 4E-BP1) [16]. Our observations
suggest that a part of the significance of PI 3-kinase
activation may lie in activation of Akt in VEGF regula-
tion of protein synthesis.
VEGF stimulated 4E-BP1 phosphorylation in a dose-
and time-dependent manner. These data suggest that
VEGF regulates early events in protein translation, lead-
ing to protein synthesis. To our knowledge, this is the
first report on regulation of protein translation by VEGF.
As described above, phosphorylation of 4E-BP-1 is re-
quired for dissociation of eIF4E, the cap-binding protein,
from the eIF4E-4E-BP1 complex. Following its release,
eIF4E may undergo phosphorylation and form eIF4F
complex with eIF4G and eIF4A. This complex binds to the
m7-cap of eukaryotic mRNA and facilitates the initiation
phase of protein translation [20]. VEGF promptly in-
duced 4E-BP1 phosphorylation in MCT cells that was
dependent on activation of PI 3-kinase, similar to our
earlier observations with insulin [11]. Observations em-
ploying Ad-DN-Akt showed that Akt activation is also
needed for VEGF stimulation of 4E-BP1 phosphoryla-
tion. Akt plays an important regulatory role in 4E-BP1
phosphorylation. There are several putative sites of phos-
phorylation in 4E-BP-1 and the process may occur in a
hierarchical manner. Thr37,46 are probably the initial tar-
gets and priming sites for phosphorylation for which Akt
activation is required [16]. It is likely that the mammalian
target of rapamycin (mTOR) is involved in phosphoryla-
tion of Ser65 and Thr70 [16, 36, 37]. Recent observations
have suggested a role of cdc2 kinase and ATM kinase
in Thr70 and Ser111phosphorylation, respectively [38, 39].
The relationship between Akt and mTOR is unclear.
mTOR has been described as a direct target of Akt
[37, 40], although nutrients may regulate mTOR activity
independent of both PI 3-kinase and Akt [21]. Our stud-
ies with the Thr37,46→Ala37,46 4E-BP1 mutant show that
phosphorylation of Thr37,46 is required for progression
to stimulation of protein synthesis and hypertrophy in
VEGF-treated cells. The direct kinases recruited by
VEGF in phosphorylating these residues need to be de-
termined. In addition to PI 3-kinase-Akt axis, Erk-1/-2
type mitogen-activated protein (MAP) kinase may also
be involved in regulation of 4E-BP1 phosphorylation
and protein synthesis. As Erk kinases are involved in
phosphorylation of eIF4E [41], it is likely that they partic-
ipate in VEGF regulation of protein synthesis.
CONCLUSION
Augmented VEGF expression associated with early
renal abnormalities in diabetes suggests that VEGF
could be a mediator of renal injury. Our observations
suggest VEGF could be a contributing factor for devel-
opment of renal hypertrophy in both type 1 and type 2
diabetes. Administration of neutralizing antibodies against
VEGF resulted in amelioration of renal hypertrophy in
animals with type 1 or type 2 diabetes [9, 42], further
suggesting a role for VEGF in regulation of renal cell
growth. A role for VEGF in nondiabetic renal injury has
been suggested in renal hypertrophy following uni-
nephrectomy [43] and in protein overload nephropathy
[44]. Our studies provide a cellular mechanism for VEGF-
induced renal hypertrophy. Additionally, being a vascu-
lar permeability factor, VEGF could participate in pro-
teinuria in diabetes. This is supported by reports that
administration of antibody against VEGF165 results in
partial amelioration of urinary protein losses in rats with
type 1 diabetes [9]. VEGF could also promote angiogen-
esis in the diabetic kidney [45], similar to its effects in
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the diabetic retina. In contrast to diabetic renal disease,
in thrombotic microangiopathy and in the remnant kid-
ney models, administration of VEGF121 is beneficial [24,
46, 47]. The varied VEGF effects in the aforementioned
renal disease models could be due to differences in prop-
erties of VEGF isoforms that may be differentially in-
volved. Alternatively, the role of VEGF in renal disease
may depend on the context of injury. Our study extends
the scope of VEGF actions beyond control of angiogen-
esis, endothelial cell differentiation, and vascular perme-
ability [48] to regulation of protein synthesis. The role
of VEGF in pathogenesis of diabetic renal disease merits
further investigation.
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